Kornimate/medical-research-clean huggingface dataset:
application of cta-based radiomic phenotyping of pcat and fluid dynamics in atherosclerotic disease (apple)

Conditions: Computed Tomography Angiography; Inflammation of Adipose Tissue; CFD

Summary: this study (apple study) intends to retrospectively enroll more than 2000 patients who who underwent ≥2 coronary computed tomography angiography (ccta) with ≥3 months interval from 11 hospitals in more than 4 provinces in china.

a multicenter, retrospective, observational trial will be conducted (apple study). to investigate whether a combined model constructed on the basis of pericoronary adipose tissue (pcat) radiomics, fluid dynamics and clinical risk factors can predict the formation of atherosclerotic plaque. it will be carried out in 11 hospitals in 4 provinces in china. the boruta algorithm and correlation proof clustering analysis were used to screen the imaging histological features, and a random forest model was used to construct an imaging histological prediction model for pcat and fluid dynamics and to construct radiomics' score. to investigate the incremental value of the radiomics' score beyond the traditional prediction model, the radiomics' score was combined with the traditional logistic regression prediction model. receiver operating characteristic (roc) curve analysis with integrated discrimination improvement (idi) and category net reclassification index (nri) were used to compare the performance of the predictive models. a ml-prediction model incorporates fai, fluid dynamics and patient clinical characteristics to identify high-risk patients in advance for patients receiving routine ccta and guide the more precise use of preventative treatments, including anti-inflammatory therapies.

Eligibility criteria:
inclusion criteria: * patients underwent cctas at least twice; * patients without any concomitant obstructive cad, or any concomitant atherosclerotic lesions in the lad on the baseline ccta; * patients without previous percutaneous coronary intervention or coronary artery bypass grafting, implanted cardiac devices, and anomalous coronary arteries as evidenced by conventional ccta. exclusion criteria: * image quality of ccta was inadequate for either mb morphological or fai or cfd analysis in either cardiac phase; * patients received other tube voltages except for 100 kvp and 120 kvp; * the interscan interval between serial cctas\< 3 months; * missing ccta data.
using device delivering ophthalmic solution in a spray form instead of eye drops

Conditions: Cataract

Summary: the purpose of the study is to confirm that vigamox reaches similar aqueous concentration when administered as the commercially available eye drops or as a spray delivered from a proprietary device.

patients scheduled for elective cataract surgery, will be randomly allocated to receive vigamox 4 times , 1 hour prior to surgery, either via the experimental device in a spray form, or via the regular, commercially available bottle. aqueous sample will be collected and submitted to a masked laboratory for measuring vigamox concentration.

Eligibility criteria:
inclusion criteria: * patients scheduled for elective cataract surgery exclusion criteria: * known allergy to quinolone compounds
a study to compare efficacy and safety of trifarotene cream when used with an oral antibiotic for the treatment of severe acne vulgaris (av)

Conditions: Acne Vulgaris

Summary: the purpose of this study was to demonstrate that daily use of topical trifarotene (cd5789) 50 microgram per gram (mcg/g) cream when used in association with oral antibiotic is safe and effective for the treatment of severe av.


Eligibility criteria:
inclusion criteria: * participants with clinical diagnosis of acne vulgaris, defined by iga score of 4 (severe) * participants with at least 20 inflammatory lesions (papules and pustules) and 30 to 120 non-inflammatory lesions (open comedones and closed comedones) and no more than 2 nodules (less than \[\<\]1 centimeter \[cm\] in diameter) on the face, excluding the nose * agrees to provide written informed consent * participant is a female of non-childbearing potential (premenarchal or postmenopausal \[absence of menstrual bleeding for 1 year prior to screening, without any other medical reason\], hysterectomy or bilateral oophorectomy) exclusion criteria: * participant with any acne cyst on the face * participants with nodulocystic or conglobate acne, acne fulminans, or secondary acne (chloracne, drug-induced acne, etc.) * participants with facial dermal conditions (example \[e.g.\] tattoo, skin abrasion, eczema, sunburned skin, scars, nevi, etc.) that may interfere with study assessments in the opinion of the investigator * participants who is at risk in terms of precautions, warnings, and contraindications for trifarotene or doxycycline hyclate * currently receiving any prescription testosterone therapy (e.g., testosterone cypionate, testosterone enanthate, testosterone pellet, testosterone undecanoate) or on a testosterone booster or prescription testosterone (e.g., dehydroepiandrosterone \[dhea\], omnadren, sustanon, testosterone cypionate, testosterone enanthate, testosterone propionate, testosterone phenylpropionate) or testosterone supplements (e.g., tribulus).
brief cognitive behavioral therapy for people with physical disabilities

Conditions: Suicide; Suicide, Attempted; Suicidal Ideation; Disability Physical; Disability Hearing; Disability, Vision

Summary: the purpose of this study is to examine the effectiveness of a psychotherapy (non-medication) treatment, brief cognitive behavioral therapy for suicide prevention, in reducing suicide ideation and attempts for people with physical disabilities.


Eligibility criteria:
inclusion criteria: * 18 years of age * disability impacting vision, hearing, or mobility * past-week suicidal ideation or past-month suicide attempt exclusion criteria: * inability to provide informed consent * lack of internet connection and web camera
solriamfetol and cbt-i in patients with insomnia disorder

Conditions: Insomnia

Summary: medication is fda approved. the objective of this project is to test the efficacy of solriamfetol for treating insomnia (alone and in combination with cognitive behavioral therapy for insomnia \[cbt-i\]). ultimately, this study will test whether wake extension (regardless of how it is achieved) will consolidate sleep and improve sleep continuity.

the current proposal is for a one-year study to investigate whether solriamfetol can improve sleep continuity and daytime performance, alone and in combination with cognitive behavioral therapy for insomnia. it is expected (given a common mechanism \[wake extension\]) that both cognitive behavioral therapy for insomnia and treatment with solriamfetol will improve sleep continuity, and that such effects will potentially be additive.

Eligibility criteria:
inclusion criteria: • participants will meet the diagnostic criteria for insomnia disorder according to diagnostic and statistical manual of mental disorders (dsm-5). in addition, the complaint of disturbed sleep will meet the following criteria: * ≥ 30 minutes to fall asleep (sl) and/or ≥ 2 awakenings per night of ≥ 15 minutes duration and/or wake after sleep onset (waso) time of ≥ 30 minutes where total sleep time (tst) did not exceed 6 hours (unless sleep efficiency \[se\] is ≤ 80%). * the problem is present for \> 3 nights per week. * the problem duration exceeds ≥ 6 months. * the complaint of impaired daytime function must include, although not limited to, the report of daytime fatigue, sleepiness, or both. * preferred regular sleep phase between 10:00 pm and 8:00 am * must garner physician's assent from their primary care clinician exclusion criteria: * use of medication expressly for the purpose of falling or staying asleep (e.g., trazodone/ desyrel, melatonin, tylenol pm, nyquil, benadryl). * night shift work * compromised renal function * major coronary artery disease and/or uncontrolled (with meds) hypertension * planning to become pregnant, pregnant, and/or breastfeeding * unstable medical or psychiatric illness * symptoms suggestive of sleep disorders other than insomnia * polysomnographic data indicating sleep disorders other than insomnia * evidence of active illicit substance use, abuse, or dependence * use of cns active medications that are for treatment of insomnia or are thought to have caused insomnia as a side effect * inadequate language comprehension * current or past experience with cbt-i * no access to the computers, i-pads, or the internet

Keywords: insomnia medication fatigue performance cbt-i
impact of neuromodulation on language impairments in stroke patients

Conditions: Stroke; Aphasia

Summary: up to 40% of stroke survivors suffer from aphasia, making recovery of language abilities a top priority in stroke rehabilitation. conventional speech and language therapy may have limited effectiveness. leveraging multimodal data (behavioral, neuroimaging, and genetics), this study aims to 1) evaluate the efficacy of combining tdcs with speech therapy, 2) examine neural changes associated with recovery, 3) identify factors influencing response to treatment.

approximately one million people in the united states are living with aphasia, an acquired neurological disorder affecting the ability to use and/or understand language. this communication impairment affects up to 40% of stroke patients. stroke victims usually prioritize speaking, writing, and walking as the three most important rehabilitation goals, two of these goals therefore involving communication. conventional speech therapy strategies have nevertheless limited effectiveness in post-stroke aphasia. indeed, approximately half of those affected will remain in this state despite intensive speech therapy. effective novel treatment is therefore warranted to improve recovery in these patients. recent evidence suggests that transcranial direct current stimulation (tdcs), a non-invasive, low-cost neuromodulation technique, applied in conjunction with speech therapy may be more effective in promoting language recovery than behavioral intervention alone. a double-blind quasi-randomized controlled study will be carried out in chronic post-stroke aphasics. participants will be assigned to either the tdcs group or to the sham (placebo) group and will receive 20 minutes of concurrent speech and language therapy by a trained speech therapist over five consecutive days. behavioral, eeg, and mri data will be acquired within one week before and after intervention. genetic samples will be collected once. secondary behavioral outcome measures will be performed again 3 months following tdcs/sham intervention to assess long-term benefits.

Eligibility criteria:
inclusion criteria: * between ages 18-85 * at least 12 months post stroke * diagnosed with aphasia due to ischemic or hemorrhagic stroke * english speaking * right handed prior to stroke exclusion criteria: * nonverbal * other neurological diseases/disorders * not mri-compatible (e.g. claustrophobia, metal implants in the head)

Keywords: transcranial direct current stimulation stroke aphasia speech therapy neurorehabilitation neuromodulation language function neuroplasticity neuroimaging eeg mri genetics language disorders
tamoxifen pharmacogenetics and clinical effects

Conditions: Breast Cancer

Summary: the purpose of this research is to try to identify which women who take tamoxifen are likely to suffer from hot flashes or are more likely to have other side effects or benefits from the drug. the researchers will do so by determining whether there are mutations that normally occur in human dna that might influence the way individuals respond to medications.

the study will test the following hypotheses. 1. there is a relationship between genetically distinct metabolic profiles of tamoxifen and the frequency and severity of hot flashes in women on chronic tamoxifen therapy. 2. genetically distinct metabolic profiles for tamoxifen effect lipid profile, bone turnover metabolites and bone mineral density, and coagulation factors. 3. different genetic profiles of estrogen responsive genes influence the pharmacodynamic effects of tamoxifen in cardiovascular system.

Eligibility criteria:
inclusion criteria: 1. 18-years or older 2. women with a prior breast cancer or who are at a high risk for developing the disease and about to start tamoxifen therapy. 3. participants must not be treated with concomitant chemotherapy or hormone therapy other than tamoxifen. they must not have ovarian ablation or currently being treated with radiation therapy and/or chronic corticosteroids. 4. the participant must not be taking anti-hot flash therapy (clonidine, bellergal, megestrol acetate). vitamin e, selective serotonin reuptake inhibitors, or herbal remedies are allowed provided that the participant has been taking the remedy for at least 4 weeks and intends to continue the remedy for at least the first month while on the study, and allows for one-month follow up evaluation (hot flash diaries and blood samples). 5. the participant must not be pregnant or lactating. 6. the participant is able and willing to sign an informed consent.

Keywords: breast cancer tamoxifen prevention
peer-based skills training to enhance teen weight loss

Conditions: Cardiovascular Diseases; Heart Diseases; Obesity

Summary: to evaluate the efficacy of peer-based skills training to enhance weight control and improve psychosocial functioning in overweight adolescents.

background: the prevalence of obesity in children, adolescents, and adults has increased significantly over the last two decades. adolescents who are obese are at great risk for remaining obese into adulthood. given the difficulty of treating adult obesity, intervening with adolescents before they reach adulthood is critical. decreasing obesity during adolescence provides an opportunity to prevent the continuance of pediatric onset obesity into adulthood. there are well-established weight control interventions for children between 8 and 12 years of age. however, treatment findings with overweight adolescents are not as robust and are difficult to replicate. one potential limitation of existing weight control interventions for adolescents is the minimal attention given to the peer group as an active component of treatment. the study was in response to an initiative issued by the national institute of diabetes and digestive and kidney diseases and entitled "innovative approaches to the prevention of obesity". the resulting grant was later reassigned to the national heart, lung, and blood institute. design narrative: a total of 119 adolescents between the ages of 13 and 16 years and between 20 and 80% overweight were randomized to one of three treatment conditions: (1) cognitive-behavioral treatment (cbt); (2) cognitive-behavioral treatment with the addition of peer-based skills training (cbt + pbst); or 3) standard care (sc). the cognitive-behavioral intervention consisted of 16 weekly sessions followed by four monthly maintenance sessions. adolescents randomized to cbt + pbst received the cognitive-behavioral treatment as well as an intensive 32 session peer-based intervention. the peer-based intervention combined problem-solving therapy with principles from outward bound to address self-reliance, social competence and physical self-worth. one way analyses of variance was conducted at the end of treatment and at 6-months after the end of treatment to compare the three groups on initial reduction in percent overweight and maintenance of decreases in percent overweight at follow-up. analysis of variance was also used to compare the three groups on measures of social functioning, self-esteem, physical activity level, and physical self-worth. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
comparison of low-dose ketamine to opioids in the management of acute pain in patients presenting to the emergency department with long bone fractures

Conditions: Pain, Acute

Summary: the purpose of this study is to establish the feasibility of initiating a ketamine pain control protocol in the emergency department for the treatment of acute pain in patients with long bone fractures and to compare the efficacy of the ketamine pain protocol to bolus morphine for pain control in the first 6 hours of patient stay in the emergency department.


Eligibility criteria:
inclusion criteria: * patients presenting to the ed with long bone fracture, open or closed.long bone fractures include:humerus, radius, ulna, femur, tibia, fibula. exclusion criteria: * received morphine in the ed prior to enrollment * received ketamine any time prior to enrollment * glasgow coma scale(gcs) less than 15 * transferred from other facility * other moderate to severe trauma injuries * contraindication to ketamine * cannot consent (no intubation, airway issues, hemodynamic instability) * prisoners * suspected and/or confirmed pregnancy
avascular necrosis (avn) long-term follow-up

Conditions: Avascular Necrosis; Femoral Head Collapse

Summary: long-term follow-up of ide patients for publication

this device (hedrocel avn intervention implant) was approved via 510(k) on april 15, 2005. one site was left open to follow patients to 5 year follow-up for publication of device survivorship.

Eligibility criteria:
inclusion criteria: * patient qualifies for core decompression based on physical exam * no history of core decompression * patient is willing and able to provide written informed consent exclusion criteria: * patient has been diagnosed as stage 0, iii, iv, v or vi using the steinberg/upenn staging system. * patient's bmi is \>40 * patient is mentally compromised * patient has neurological condition in ipsilateral or contralateral limb, which affect lower limb function * the patient has had a proximal femoral osteotomy or internal fixation in the affected hip. * the patient has undergone previous treatment for avn * previous hip conditions * patient's bone stock is insufficient * patient has diagnosed systemic disease * patient is a pregnant female * patient is unable or unwilling to attend postop follow-up visits * patient has received investigational drug within the previous 6 months or an investigational device within the last 12 months * patient has an active or latent infection * patient has metal sensitivity * patient is a prisoner

Keywords: avn femoral head collapse
a study of anakinra to prevent or treat severe side effects for patients receiving car-t cell therapy

Conditions: B Cell ALL; B-Cell Lymphoma; B-cell Non Hodgkin Lymphoma

Summary: this study is being done to see if the investigational drug, anakinra, prevent or reverse the severe side effects caused by car-t cell therapy.


Eligibility criteria:
inclusion criteria: * patients (age \>/= 18) with a diagnosis of relapsed cd19+ b-cell all, mcl, or nhl receiving commercially approved cd19-specific car t cells (e.g. tisagenleuleucel, axicabtagene, brexucabtagene autoleucel, etc) are eligible for the study exclusion criteria: * patients with uncontrolled systemic fungal and bacterial infections * patients with known hypersensitivity to e. coli-derived proteins * women of childbearing potential must have a negative serum or urine pregnancy test (women who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential) * women who are pregnant or breastfeeding
prediction of significant liver fibrosis

Conditions: Liver Fibrosis

Summary: the deep learning method based on convolutional neural network (cnn) was used to extract the relevant features of liver fibrosis classification from the multi-modal information of digital pathological sections, clinical parameters and biomarkers of a large number of existing cases of liver puncture, and the u-net architecture of cnn was used to segment and extract the features of clinical medical images.

patients with chronic hepatitis b underwent b-ultrasound-guided liver biopsy, and were divided into mild liver fibrosis group (fibrosis grade 0-1, s1), significant liver fibrosis group (fibrosis grade 2, s2), advanced liver fibrosis group and early cirrhosis group (fibrosis grade 3-4, s3-4) according to the pathological results.in this study, 200 patients with different degrees of liver fibrosis and 200 normal volunteers were collected from 2018 to 2022, and their clinical biochemical data, imaging data and peripheral blood samples were collected.the pathological microenvironment characteristics, imaging characteristics, clinical parameter characteristics and other data of patients were extracted, and the distillation learning method based on teacher-student model was adopted to develop and construct a multi-modal big data analysis model for accurate grading of liver fibrosis, so as to achieve a non-invasive intelligent grading diagnosis system for liver fibrosis.

Eligibility criteria:
inclusion criteria: 1. age of 18-60 years old 2. the diagnosis of chronic hepatitis b is in line with the diagnostic criteria of china's 2019 chronic hepatitis b prevention and treatment guidelines, and the diagnosis of non-alcoholic fatty liver is in line with the asian pacific hepatology association guidelines 3. imaging showed no liver cancer exclusion criteria: 1. there are contraindications for liver biopsy 2. liver pathology did not meet the criteria

Keywords: chronic hepatitis liver fibrosis artificial intelligence auxiliary diagnosis
intraperitoneal bupivacaine for pelvic organ prolapse

Conditions: Pelvic Organ Prolapse

Summary: the purpose of this study is to evaluate the effects of 30 ml intraperitoneal bupivacaine without epinephrine 0.25% on postoperative pain control in patients undergoing pelvic organ prolapse repair. the investigators hypothesize that use of intraperitoneal bupivacaine will decrease postoperative pain scores and opiate consumption in the postoperative period, following pelvic organ prolapse repair.


Eligibility criteria:
4.1 inclusion criteria list the criteria: * age \>= 18 years * access to cell phone with text messaging capabilities (for same day surgery discharge) * patients undergoing pelvic organ prolapse repair with peritoneal access 4.2 exclusion criteria list the criteria: * bupivacaine allergy * history of epilepsy or other seizure disorder * ekg demonstrating asymptomatic sinus bradycardia \<40 bpm, symptomatic sinus bradycardia \<60 bpm, first degree av block, second degree av block, third degree av block, prolonged qt, atrial fibrillation, supraventricular tachycardia, or myocardial infarction * chronic liver disease proved by any alt or ast elevation greater than 2x upper limit of normal * serum bilirubin elevation in excess of 5 mg/dl * g6pd deficiency * weight less than 100 lbs * chronic opiate use
a study of the effect of laughter therapy on the mental health and quality of survival of hematopoietic stem cell transplant patients

Conditions: Hematologic Malignancy; Hematopoietic Stem Cell Transplant

Summary: 主要研究目的： 1)探讨笑疗法在造血干细胞移植患者移植心理健康及生存质量中的效果。 次要研究目的： 1. 了解造血干细胞移植患者移植后3个月、6个月、1年内的心理健康变化和生存质量水平； 2. 探讨笑疗法在造血干细胞移植患者预后等结局指标中的应用效果。

本研究将采用单中心、前瞻性的平行随机对照试验对2024年12月1日至2025年12月1日期间首次接受造血干细胞移植的患者进行招募。对照组实施常规护理措施和出院的常规延续护理措施，干预组从移植+1天开始进行笑治疗，住院期间为移植后+1天至出仓，按照笑的口令"hihihi（拼音拼读），哈哈哈，茄子茄子茄子，七喜七喜七喜，哈哈哈哈哈哈"，30遍口令为1次训练，1天进行1次。出仓及出院后，干预组患者集中线上笑疗法干预，1次/周，重复30遍口令，至移植后1年。分别于移植后3个月、6个月、1年对两组患者在预后、疲劳、焦虑及抑郁、幸福感以及创伤后成长、生存质量及结局指标上进行组间比较，明确笑疗法在造血干细胞移植患者心理健康及生存质量中的效果。

Eligibility criteria:
inclusion criteria: patients with a pathologically confirmed diagnosis of hematologic malignancy; patients undergoing their first hematopoietic stem cell transplant; age ≥ 16 years; those who have some reading and writing ability; those who can cooperate in completing the questionnaires and assessments; informed consent and voluntary participation in the study. exclusion criteria: those with severe mental illness or personality disorders; those who cannot operate a smartphone independently; those with severe visual and hearing impairments; those who are critically ill and cannot receive the intervention.